Website Preloader
Website Preloader

BETTER HEALTH FOR BETTER FUTURE

Learn more

Our Company

About Us

MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company pioneered the new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous indications.

Our Mission

Revolutionize the way we attack serious human diseases.

Our Primary Focus Areas

SPINE FUSION

OxyFuse-133® is an oxysterol-based osteoinductive investigational device that stimulates bone formation by targeting specialized stem cells.

NASH/MASH

Oxy210, an orally bioavailable oxysterol-based drug candidate with antifibrotic and anti-inflammatory properties, is being developed as a safe and effective treatment for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH).

Funding Institutions

Collaborations